X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2851) 2851
Publication (363) 363
Conference Proceeding (103) 103
Book Review (34) 34
Magazine Article (12) 12
Book Chapter (3) 3
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pembrolizumab (2888) 2888
oncology (1596) 1596
nivolumab (1416) 1416
immunotherapy (1369) 1369
index medicus (1332) 1332
humans (927) 927
ipilimumab (853) 853
cancer (845) 845
melanoma (808) 808
chemotherapy (803) 803
open-label (605) 605
metastasis (526) 526
patients (502) 502
tumors (462) 462
docetaxel (457) 457
lung cancer (442) 442
care and treatment (418) 418
female (415) 415
male (414) 414
pd-1 (409) 409
survival (389) 389
immunology (387) 387
pd-l1 (385) 385
middle aged (371) 371
immune checkpoint (364) 364
safety (360) 360
apoptosis (352) 352
aged (349) 349
cancer therapies (347) 347
clinical trials (344) 344
multicenter (337) 337
therapy (324) 324
metastases (289) 289
blockade (287) 287
cell lung-cancer (279) 279
pd-1 protein (275) 275
metastatic melanoma (262) 262
research (256) 256
expression (255) 255
respiratory system (252) 252
programmed cell death 1 receptor - antagonists & inhibitors (250) 250
pd-l1 protein (244) 244
lymphocytes (241) 241
analysis (236) 236
adult (234) 234
atezolizumab (233) 233
pd-1 blockade (223) 223
lung cancer, non-small cell (215) 215
antibodies, monoclonal - therapeutic use (213) 213
biomarkers (211) 211
advanced melanoma (209) 209
cell death (203) 203
immunotherapy - methods (203) 203
treatment outcome (202) 202
prognosis (201) 201
mutation (200) 200
antineoplastic agents - therapeutic use (199) 199
melanoma - drug therapy (199) 199
drug therapy (197) 197
immune checkpoint inhibitors (197) 197
ligands (197) 197
neoplasms. tumors. oncology. including cancer and carcinogens (197) 197
medical research (193) 193
antibodies, monoclonal, humanized - therapeutic use (192) 192
checkpoint inhibitors (183) 183
aged, 80 and over (182) 182
immunohistochemistry (175) 175
anti-pd-1 (172) 172
non-small cell lung carcinoma (172) 172
medicine, research & experimental (171) 171
medicine & public health (170) 170
non-small cell lung cancer (169) 169
medical prognosis (165) 165
antibodies (161) 161
adverse events (159) 159
antineoplastic agents, immunological - therapeutic use (156) 156
carcinoma (154) 154
review (151) 151
toxicity (151) 151
health aspects (150) 150
cytotoxicity (148) 148
pharmacology & pharmacy (148) 148
lung neoplasms - drug therapy (147) 147
usage (147) 147
lymphocytes t (146) 146
t-cells (146) 146
programmed cell death 1 receptor - immunology (145) 145
nsclc (143) 143
trial (142) 142
immune system (141) 141
antibodies, monoclonal, humanized - adverse effects (138) 138
article (136) 136
inhibitors (135) 135
antibody (132) 132
antibodies, monoclonal - adverse effects (128) 128
case report (125) 125
hematology (124) 124
melanoma - pathology (124) 124
antigens (122) 122
carcinoma, non-small-cell lung - drug therapy (122) 122
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2822) 2822
German (40) 40
French (39) 39
Korean (10) 10
Russian (7) 7
Spanish (7) 7
Japanese (3) 3
Czech (2) 2
Icelandic (1) 1
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Der Urologe. Ausg. A, ISSN 0340-2592, 01/2019, Volume 58, Issue 1, pp. 45 - 48
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2019, Volume 37, Issue 11, pp. 940 - 940
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 17, pp. 1658 - 1667
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II... 
ONCOLOGY | NIVOLUMAB | PEMBROLIZUMAB | Rapid Communications
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2018, Volume 16, Issue 11, pp. 1376 - 1378
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4, pp. 383 - 390
Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with... 
ACQUIRED-RESISTANCE | PEMBROLIZUMAB | ONCOLOGY | COMBINATION | IPILIMUMAB
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 03/2016, Volume 14, Issue 3, pp. 255 - 264
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines... 
PEMBROLIZUMAB | ONCOLOGY | NIVOLUMAB | IMMUNOTHERAPY | SAFETY | DOCETAXEL
Journal Article
European Journal of Cancer, ISSN 0959-8049, 07/2019, Volume 116, pp. 178 - 181
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2019, Volume 113, pp. 69 - 71
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 6/2019, Volume 25, Issue 7, pp. 1008 - 1009
Journal Article
International Journal of Dermatology, ISSN 0011-9059, 06/2019, Volume 58, Issue 6, pp. 739 - 741
Journal Article
Clinical and Experimental Dermatology, ISSN 0307-6938, 07/2019, Volume 44, Issue 5, pp. 570 - 573
Click here for the corresponding questions to this CME article. 
DERMATOLOGY | Radiation | Pembrolizumab
Journal Article
by Arays, R and Wang, P
Scandinavian Journal of Immunology, ISSN 0300-9475, 07/2018, Volume 88, Issue 1, pp. e12677 - n/a
Pembrolizumab is a monoclonal antibody directed against programmed cell death 1 (PD-1) which is an important immune-checkpoint receptor that is expressed by... 
ADVERSE EVENTS | IMMUNOLOGY | Pembrolizumab
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2018, Volume 36, Issue 14, pp. 1387 - 1388
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2018, Volume 16, Issue 11, pp. 1376 - 1378
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4, pp. 391 - 398
Purpose The clinical activity observed in a phase I dose-escalation study of concurrent therapy with nivolumab (NIVO) and ipilimumab (IPI) in patients with... 
UNTREATED MELANOMA | DABRAFENIB | PEMBROLIZUMAB | MONOTHERAPY | ONCOLOGY | TRAMETINIB | Original Reports
Journal Article
Journal of Oncology Practice, ISSN 1554-7477, 09/2018, Volume 14, Issue 9, pp. 539 - 540
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.